Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LX1033 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | 500 mg LX1033 two times daily |
| Mid dose | EXPERIMENTAL | 500 mg LX1033 three times daily |
| High dose | EXPERIMENTAL | 1000 mg LX1033 two times daily |
| Placebo | PLACEBO_COMPARATOR | Matching placebo dosing |
| Name | Type | Description |
|---|---|---|
| 250 mg LX1033 tablets | DRUG | 250 mg LX1033 tablets administered orally |
| Placebo tablet | DRUG | Matching placebo tablet administered orally |
Inclusion Criteria: * Male and female subjects, aged 18 to 70 years, with diarrhea-predominant IBS (IBS-D) with symptom onset at least 6 months prior to diagnosis * Two or more days per week with at least one stool with a consistency of Type 6 or 7 (Bristol Stool Form Scale) * Weekly average of wor...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 2 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE2 | LY3537031 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | Camlipixant |
LX1033 is an investigational small molecule developed by Lexicon Pharmaceuticals, Inc. for irritable bowel syndrome. It was studied specifically in patients with diarrhea-predominant IBS. LX1033 has completed a Phase 2 clinical trial and is not an approved therapy. It is also referred to as 250 mg LX1033 tablets.
LX1033 was being developed for the treatment of irritable bowel syndrome, specifically the diarrhea-predominant subtype. Its clinical program evaluated safety and efficacy in adults with this condition. LX1033 remains investigational and is not approved for any use.
LX1033 is developed by Lexicon Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker LXRX. Lexicon is the sponsor of the clinical program evaluating LX1033 in irritable bowel syndrome.
LX1033 has completed a Phase 2 clinical trial in irritable bowel syndrome. It is an investigational drug and has not been approved by the FDA. No active trials of LX1033 are currently listed.
LX1033 was evaluated in one completed Phase 2 trial, NCT01494233, titled a multi-center trial to determine the safety and efficacy of LX1033 in subjects with diarrhea-predominant irritable bowel syndrome. The trial enrolled 373 participants across sites in the United States and was randomized, double-blind, and placebo-controlled.